Switching to camizestrant after ESR1 mutation detection prolongs progression free survival in advanced breast cancer

1. In patients with ER-positive, HER2-negative advanced breast cancer who developed an ESR1 mutation during first-line aromatase inhibitor plus CDK4/6 inhibitor therapy, those who switched to camizestrant while continuing the CDK4/6 inhibitor had longer progression-free survival (PFS) compared to those who continued the aromatase inhibitor. 2. The switch to camizestrant was also associated with a longer […]